ProteinQure Inc.
TORONTO, ON / ACCESSWIRE / March 25, 2024 / ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in the fight against triple-negative breast cancer (TNBC). The novel Peptide Drug Conjugate (PDC) designed by ProteinQure demonstrated exceptional efficacy in a comprehensive suite of Patient-Derived Xenograft (PDX) models. The experiments were conducted in the lab of Dr. David Cescon at the Princess Margaret Cancer Centre/University Health Network, one of the world's top five cancer research centres.
Developed through ProteinQure's cutting-edge computational platform, the innovative SORT1 targeting PDC is a novel peptide attached to a highly potent chemotherapeutic agent. The drug candidate was tested across a broad range of breast cancer models. The results demonstrated remarkable antitumor efficacy, including cancers resistant to standard chemotherapies and antibody-drug conjugates.
"Working with the David Cescon Lab at UHN has been instrumental in validating our novel PDC's efficacy against one of the most challenging forms of breast cancer. Based on these results, we are moving our lead program forward into IND-Enabling studies and our first clinical trial," said Lucas Siow, CEO of ProteinQure. "These findings not only highlight the power of our computational drug design platform but also represent significant validation in our quest to develop tissue-specific peptides for targeted drug delivery."
ProteinQure's collaborators will present the data at the upcoming American Association for Cancer Research (AACR) conference in San Diego. The AACR conference, renowned for showcasing the latest innovations in cancer research, provides the perfect stage to share these findings with the global cancer research community.
"We are excited to present this data at AACR and help develop new therapeutic options for breast cancer, especially with promising Canadian startups," stated Dr. David Cescon, head of the lab at UHN. "The success of this unique PDC in diverse PDX models is a testament to the potential of combining advanced computational techniques, precision oncology, and our labs' robust preclinical platform".
Funding for parts of this work included contributions from IRAP-Canada and the INOVAIT program based out of Sunnybrook Hospital.
Poster Presentation Details:
Title: In-vivo efficacy of a novel peptide-conjugated drug in patient-derived xenograft models of breast cancer
Session Title: New Targets
Date and Time: Tuesday, April 9, at 1:30 p.m. PT/4:30 p.m. ET
Abstract Number: 5911
Speaker: Mitchell Elliott, UHN Princess Margaret Cancer Centre
About ProteinQure
ProteinQure is a pioneering startup specializing in the computational design of peptide drugs utilizing state-of-the-art artificial intelligence and molecular simulation technologies. With a focus on precision medicine, ProteinQure is dedicated to transforming the landscape of drug development and ushering in a new era of targeted effective treatments.
About the David Cescon Lab at UHN
The David Cescon Lab at the University Health Network is a leader in breast cancer research, focusing on the mechanisms of cancer progression and resistance to therapy. Through cutting-edge pre-clinical and clinical research and collaborations, the lab develops novel therapeutic strategies aimed at improving outcomes for cancer patients worldwide.
For further information, please contact:
Lucas Siow - CEO of ProteinQure - press@proteinqure.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
SOURCE: ProteinQure Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Florence Connects 65,000+ Study Sites and 600+ Sponsors Worldwide - Unleashing the Next Era of Clinical Trial Intelligence23.10.2025 14:00:00 CEST | Press release
With the industry's largest network of sites, Florence sets a new benchmark for AI-enabled study startup, workflow automation, and operational risk management. ATLANTA, GA / ACCESS Newswire / October 23, 2025 / Florence Healthcare reinforced its position as the global leader in clinical trial operations with a major milestone: Florence Trial Operations Platform now connects 65,000 study sites spanning more than 600 sponsors across 90+ countries, forming the industry's largest network. Recognized as the #1 clinical trial technology for six consecutive years, Florence continues to set the standard for startup speed, workflow automation, and operational risk management across sponsor study portfolios. "Florence was built to bring sponsors and sites into a shared operational space," said Ryan Jones, CEO of Florence Healthcare. "First, we fully digitized startup to eliminate manual bottlenecks and paper workflows. Now, we're using AI to enhance speed and augment intelligence across 65,000 s
U.S. Polo Assn. Wins Gold and Silver Stevie Awards at the 2025 International Business Awards in Lisbon, Portugal23.10.2025 13:00:00 CEST | Press release
LISBON, PT AND WEST PALM BEACH, FL / ACCESS Newswire / October 23, 2025 / USPA Global today announced that U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has been awarded two prestigious Stevie® Awards from the 22nd Annual International Business Awards® (IBA).U.S. Polo Assn. Wins Two Stevie® Awards U.S. Polo Assn. was celebrated during an elegant gala event at the Corinthia Hotel in Lisbon, Portugal, on Friday, October 10, attended by leadership from USPA Global and the brand's strategic partners in the region. The global event hosted over 350 guests from more than 30 nations, including many of the world's top companies and Stevie winners, including Coca-Cola, Starbucks, Lenovo, Kendra Scott, IBM, and Turkish Airlines. The brand's winning entries included a Gold Stevie Award for 'Achievement in International Expansion' and a Silver Stevie Award in 'Celebration Event' for the 2024 Paris Games Polo Challenge campaign. The multi-billion-dollar, sp
Fortune 500 Leaders Share AI-powered Supply Chain Excellence on Stage at OMP Conference22.10.2025 11:00:00 CEST | Press release
Industry giants, including AstraZeneca, Johnson & Johnson, General Mills, and Kraft Heinz, to present real-world case studies in Miami MIAMI, FL / ACCESS Newswire / October 22, 2025 / OMP, a global leader in supply chain planning solutions, announced its lineup of customer speakers for the OMP REAL Conference 2025, taking place November 18-19 in Miami. The event will gather industry leaders, technology innovators, and supply chain experts to share how AI-powered supply chain planning delivers real business results. Speakers include executives from world-leading organizations, including Arxada,AstraZeneca, Beiersdorf, Eastman, Johnson & Johnson, Kraft Heinz, Land O'Lakes, and Visy. They will share real-world case studies of how they're leveraging OMP's Unison Planning™ to boost supply chain agility, resilience, and sustainability. Explore the program. Conference theme: REAL This year's theme - Real expertise. Real solutions. Real results. - underscores OMP's commitment to deliver tangib
Oman Hosts the Oman Investment Forum 2025 in the United Kingdom22.10.2025 08:00:00 CEST | Press release
Reform Metrics and Global Outlook Underpin London Gathering LONDON, UK, OM / ACCESS Newswire / October 22, 2025 / The Sultanate of Oman, represented by the Ministry of Finance in cooperation with the Ministry of Foreign Affairs, held the Oman Investment Forum 2025 in London to deepen financial, investment, and economic cooperation between the two nations. The event underscored the strategic weight of the Oman-UK partnership and the role of the Strategic Advisory Group (SAG), established in 2018 as the institutional mechanism through which the two countries coordinate investment, fiscal reform, and economic-diversification strategy. Oman enters this year's forum with one of the strongest fiscal positions in the region. Foreign Direct Investment (FDI) reached USD 78.8 billion by the end of the second quarter of 2025, a 12.8 percent increase compared to 2024. Inflows during the first half of 2025 totalled USD 8.8 billion, reflecting rising international confidence. Omani officials opened
Malaysia Expands Deployment of BlackBerry Secure Communications for the 46th and 47th ASEAN Summits22.10.2025 05:00:00 CEST | Press release
Malaysia modernizes mobile command and control, securing voice and messaging for inter-agency coordination with BlackBerry AtHoc and BlackBerry SecuSUITE KUALA LUMPUR, MY / ACCESS Newswire / October 21, 2025 / BlackBerry Limited (NYSE:BB)(TSX:BB) today announced that Malaysia has deployed BlackBerry® AtHoc® and BlackBerry® SecuSUITE® to secure communications and protect people during the ASEAN Summit events in 2025, including the 46th ASEAN Summit held in May, and the 47th ASEAN Summit taking place in Kuala Lumpur from October 26 to 28. The ASEAN Summits are among the region's most complex diplomatic events, involving more than 500 meetings and thousands of personnel across multiple government agencies. Coordinated by Malaysia's Ministry of Foreign Affairs through the ASEAN Main Logistics Secretariat (SILA), the Summits bring together heads of state, ministers, and officials from ASEAN member countries and key partners across the Americas, Europe, Africa, and Asia. Following a successf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom